Evaluation of pancreatic elastase-1 measurement during health checkups for detection of pancreatic cancer in asymptomatic individuals

Q3 Medicine

Cancer treatment and research communications Pub Date : 2025-01-01 DOI:10.1016/j.ctarc.2025.100951

Haruka Itoh , Satomi Asai , Shinji Takashimizu , Toshio Nakagohri , Yasuhiro Nishizaki , Hayato Miyachi

{"title":"Evaluation of pancreatic elastase-1 measurement during health checkups for detection of pancreatic cancer in asymptomatic individuals","authors":"Haruka Itoh , Satomi Asai , Shinji Takashimizu , Toshio Nakagohri , Yasuhiro Nishizaki , Hayato Miyachi","doi":"10.1016/j.ctarc.2025.100951","DOIUrl":null,"url":null,"abstract":"<div><h3>Objectives</h3><div>Early detection of pancreatic cancer before symptom onset improves curability. This study evaluated the utility of blood elastase-1 as a screening tool for pancreatic cancer in asymptomatic individuals.</div></div><div><h3>Methods</h3><div>A total of 200,583 individuals underwent health checkups at the Tokai University Hospital Health Screening Center between July 2005 and December 2018. The incidence of pancreatic cancer was compared among individuals with blood elastase-1 levels ≥401 ng/dL or <401 ng/dL at health checkups.</div></div><div><h3>Results</h3><div>Among 376 individuals with elastase-1 levels ≥401 ng/dL (high group), 12 were diagnosed with pancreatic cancer at our hospital. Among 200,207 records with elastase-1 levels <401 ng/dL (low group), an estimated 41 individuals developed pancreatic cancer. The sensitivity and specificity of elastase-1 testing for pancreatic cancer detection was 22.6 % and 99 %, respectively. The sensitivity of abdominal ultrasonography was 50 % and increased to 68.8 % when combined with elastase-1 testing. In patients diagnosed with pancreatic cancer, the elastase-1-high group was more likely to undergo surgery, as compared with the elastase-1-low group (75 % [9/12] vs. 50 % [10/20], statistically not signifcant, p= 0.267), and had significantly longer overall survival (median: 1113 days and 641 days).</div></div><div><h3>Conclusions</h3><div>Incorporating elastase-1 testing alongside abdominal ultrasonography in routine health checkups may improve the detection of pancreatic cancer in asymptomatic individuals. Patients whose pancreatic cancer was identified due to elevated elastase-1 levels had a better prognosis compared to those diagnosed through other methods.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"44 ","pages":"Article 100951"},"PeriodicalIF":0.0000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer treatment and research communications","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2468294225000875","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives

Early detection of pancreatic cancer before symptom onset improves curability. This study evaluated the utility of blood elastase-1 as a screening tool for pancreatic cancer in asymptomatic individuals.

Methods

A total of 200,583 individuals underwent health checkups at the Tokai University Hospital Health Screening Center between July 2005 and December 2018. The incidence of pancreatic cancer was compared among individuals with blood elastase-1 levels ≥401 ng/dL or <401 ng/dL at health checkups.

Results

Among 376 individuals with elastase-1 levels ≥401 ng/dL (high group), 12 were diagnosed with pancreatic cancer at our hospital. Among 200,207 records with elastase-1 levels <401 ng/dL (low group), an estimated 41 individuals developed pancreatic cancer. The sensitivity and specificity of elastase-1 testing for pancreatic cancer detection was 22.6 % and 99 %, respectively. The sensitivity of abdominal ultrasonography was 50 % and increased to 68.8 % when combined with elastase-1 testing. In patients diagnosed with pancreatic cancer, the elastase-1-high group was more likely to undergo surgery, as compared with the elastase-1-low group (75 % [9/12] vs. 50 % [10/20], statistically not signifcant, p= 0.267), and had significantly longer overall survival (median: 1113 days and 641 days).

Conclusions

Incorporating elastase-1 testing alongside abdominal ultrasonography in routine health checkups may improve the detection of pancreatic cancer in asymptomatic individuals. Patients whose pancreatic cancer was identified due to elevated elastase-1 levels had a better prognosis compared to those diagnosed through other methods.

查看原文本刊更多论文

评估胰腺弹性酶-1测量在健康检查中检测胰腺癌的无症状个体

目的在症状出现前及早发现胰腺癌，提高治愈率。本研究评估了血液弹性酶-1作为无症状个体胰腺癌筛查工具的效用。方法2005年7月至2018年12月，共有200,583人在东海大学医院健康筛查中心接受了健康检查。比较健康检查时血液弹性酶-1水平≥401 ng/dL或≥401 ng/dL的个体胰腺癌的发病率。结果376例弹性酶-1水平≥401 ng/dL（高组）患者中，12例在我院确诊为胰腺癌。在200,207例弹性酶-1水平为401 ng/dL（低组）的记录中，估计有41人患上了胰腺癌。弹性酶-1检测胰腺癌的敏感性和特异性分别为22.6%和99%。腹部超声检查的敏感性为50%，结合弹性酶-1检测可提高至68.8%。在诊断为胰腺癌的患者中，与弹性酶-1低组相比，弹性酶-1高组更有可能接受手术（75%[9/12]对50%[10/20]，统计学上无统计学意义，p= 0.267），总生存期明显更长（中位数：1113天和641天）。结论在常规健康检查中结合腹部超声检查弹性酶-1检测可提高无症状患者胰腺癌的检出率。与通过其他方法诊断的胰腺癌患者相比，因弹性酶-1水平升高而确诊的胰腺癌患者预后更好。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer treatment and research communications Medicine-Oncology

CiteScore

4.30

自引率

0.00%

发文量

148

审稿时长

56 days

期刊介绍： Cancer Treatment and Research Communications is an international peer-reviewed publication dedicated to providing comprehensive basic, translational, and clinical oncology research. The journal is devoted to articles on detection, diagnosis, prevention, policy, and treatment of cancer and provides a global forum for the nurturing and development of future generations of oncology scientists. Cancer Treatment and Research Communications publishes comprehensive reviews and original studies describing various aspects of basic through clinical research of all tumor types. The journal also accepts clinical studies in oncology, with an emphasis on prospective early phase clinical trials. Specific areas of interest include basic, translational, and clinical research and mechanistic approaches; cancer biology; molecular carcinogenesis; genetics and genomics; stem cell and developmental biology; immunology; molecular and cellular oncology; systems biology; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; cancer policy; and integration of various approaches. Our mission is to be the premier source of relevant information through promoting excellence in research and facilitating the timely translation of that science to health care and clinical practice.